Free tool
FAERS Monitor: Climara
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020375 or its brand name (Climara, Estradiol). Reports on generic versions are filed under their own applications.
Reports
57,593
Serious
24,115
42% of reports
Hospitalization
7,644
Death reported
958
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product adhesion issue5,459
- drug ineffective5,040
- headache3,312
- nausea3,167
- fatigue3,124
- off label use2,704
- hot flush2,356
- pain2,237
- diarrhoea2,071
- dizziness1,911
- breast cancer female1,833
- rash1,825
- arthralgia1,783
- pruritus1,777
- insomnia1,647
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 612 |
| 2005 | 703 |
| 2006 | 535 |
| 2007 | 1,547 |
| 2008 | 1,032 |
| 2009 | 864 |
| 2010 | 1,164 |
| 2011 | 1,184 |
| 2012 | 1,414 |
| 2013 | 1,075 |
| 2014 | 1,321 |
| 2015 | 2,351 |
| 2016 | 2,855 |
| 2017 | 2,725 |
| 2018 | 3,011 |
| 2019 | 3,511 |
| 2020 | 3,484 |
| 2021 | 3,486 |
| 2022 | 3,548 |
| 2023 | 4,070 |
| 2024 | 4,307 |
| 2025 | 6,292 |
| 2026 | 6,501 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,996,566 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product adhesion issueSignal | 5,459 | 65.7 | 63.9 | 295,028 |
| breast cancer femaleSignal | 1,833 | 26.8 | 25.6 | 42,489 |
| hot flushSignal | 2,356 | 11.8 | 11.3 | 22,522 |
| insomniaSignal | 1,647 | 2.3 | 2.2 | 1,171 |
| headache | 3,312 | 1.9 | 1.9 | 1,531 |
| pruritus | 1,777 | 1.7 | 1.6 | 509 |
| arthralgia | 1,783 | 1.6 | 1.5 | 373 |
| rash | 1,825 | 1.5 | 1.5 | 341 |
| fatigue | 3,124 | 1.5 | 1.4 | 480 |
| nausea | 3,167 | 1.5 | 1.4 | 480 |
| dizziness | 1,911 | 1.4 | 1.3 | 223 |
| drug ineffective | 5,040 | 1.4 | 1.4 | 607 |
| pain | 2,237 | 1.3 | 1.3 | 189 |
| diarrhoea | 2,071 | 1.2 | 1.1 | 54 |
| off label use | 2,704 | 1.1 | 1.1 | 41 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.